Patients with six different cancer types, including those with cervical, bladder, ovarian and lung tumors, have responded positively to the new treatment.
Since these patients had already exhausted their other treatment options, the drug could be ready to extend their lifespans within the next five years.
The innovative new drug, called tisotumab vedotin (or TV for short), releases a toxic substance to kill cancer cells from within. The results have been so positive, the drug has now moved forward to phase II trials in cervical cancer and will be tested in a range of additional solid tumor cancers.
A team at The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust led a phase I/II global clinical trial of nearly 150 European patients with a variety of cancer types who had stopped responding to standard treatments.
Researchers saw responses in 27% of patients with bladder cancer, 26.5% of those with cervical cancer, 14% for ovarian cancer, 13% with esophageal, 13% with non-small cell lung, and 7% with endometrial cancer (although not in any men with prostate cancer).
Responses lasted an average of 5.7 months, and up to 9.5 months in some patients. The main side effects reported from the study were nose bleeds, fatigue, nausea and eye problems – but halfway through the trial the researchers adjusted the protocol to reduce these eye-related effects.
TV is made up of a toxic drug attached to the tail end of an antibody. The antibody is designed to seek out a receptor called “tissue factor” – present at high levels on the surface of many cancers cells and linked with worse survival rates. Binding to the tissue factor draws the drug inside cancer cells, where it can kill them from within.
The trial initially recruited 27 patients to assess safety and establish the right dose, before expanding to a further 120 patients primarily to look at whether the drug was hitting the right target but also to examine its effects on tumors.
The majority of patients in the early trial had advanced-stage cancer (spread locally or around the body) that had already been treated with, and became resistant to, an average of three different types of treatment.
“What is so exciting about this treatment is that its mechanism of action is completely novel – it acts like a Trojan horse to sneak into cancer cells and kill them from the inside,” said Professor Johann de Bono from The Institute of Cancer Research, London.
“TV has manageable side effects, and we saw some good responses in the patients in our trial, all of whom had late-stage cancer that had been heavily pre-treated with other drugs and who had run out of other options.
“We have already begun additional trials of this new drug in different tumor types and as a second-line treatment for cervical cancer, where response rates were particularly high. We are also developing a test to pick out the patients most likely to respond.”
Biopsy samples taken at the start of the trial are currently being analyzed for expression of tissue factor on tumor cells to see if it could be used as a marker to select patients most likely to respond to the drug.
Professor Paul Workman, Chief Executive of The Institute of Cancer Research, London, said: “We’ve seen major advances against cancer in recent decades, but many tumor types remain very difficult to treat once the cancer has begun to spread. We desperately need innovative treatments like this one that can attack cancers in brand new ways, and remain effective even against tumors that have become resistant to standard therapies.
“It’s exciting to see the potential shown by TV across a range of hard-to-treat cancers. I look forward to seeing it progress in the clinic and hope it can benefit patients who currently have run out of treatment options.”
(Source: The Institute of Cancer Research, London)
Cure Your Friends’ Negativity By Sharing The Good News On Social Media – Photo by National Cancer Institute, CC